Source comparison
Thymosin Alpha-1 Protocol: Dosing Comparison Across Clinical Scenarios
Chronic viral reactivation (EBV, HHV-6) 1.6–3.2mg Twice weekly 12–16 weeks Viral titer reduction >40%, CD4/CD8 normalization Effective when combined with antiviral nutraceuticals; monitor liver enzymes if using high-dose monolaurin concurrently Autoimmune flar
This comparison does not assign a generated winner or score.
- Chronic viral reactivation (EBV, HHV-6)
- 1.6–3.2mg
- Twice weekly
- 12–16 weeks
- Viral titer reduction >40%, CD4/CD8 normalization
- Effective when combined with antiviral nutraceuticals; monitor liver enzymes if using high-dose monolaurin concurrently
- Autoimmune flare modulation (Hashimoto's, RA)
- 1.6mg
- 16–24 weeks
- T-reg expansion (CD4+CD25+FoxP3+), reduced anti-TPO or RF titers
- Works best during active flare with elevated inflammatory markers; less effective in remission phases
- Post-COVID immune exhaustion
- 3.2mg
- 8–12 weeks
- Restored NK cytotoxicity >20%, normalized IL-6
- Short-duration high-dose approach; pair with mitochondrial support (CoQ10, NAD+ precursors) for symptom resolution
- Cancer adjunct (post-chemo immune recovery)
- 6.4mg
- 12–24 weeks
- CD4/CD8 >1.0, lymphocyte count >1500/µL
- Highest evidence base; used in clinical oncology in some countries; requires oncologist co-management
- Preventive immune optimization (no active disease)
- Once weekly
- Ongoing
- Maintain CD4/CD8 1.5–2.5, NK >25%
- Questionable cost-benefit ratio; reserve for documented immune deficiency or high infectious disease exposure risk
- Functional medicine practitioners who prescribe thymosin alpha-1 for 'general immune support' without measurable immune dysfunction are practicing outside evidence. The peptide corrects dendritic cell signaling deficits, not baseline wellness. If immune panels are normal, thymosin alpha-1 offers no additional benefit and represents an expense without mechanism.